Antibiotics to lower C-section risk during labor induction for first-time moms with obesity
Antibiotic Prophylaxis to Prevent Obesity-related Induction Complications in Nulliparae at Term (APPOINT 2.0)
This gives antibiotics during labor to first-time pregnant women with obesity who are induced at term to reduce the chance of cesarean delivery.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Oklahoma Hlth Sciences Ctr NIH-funded |
| Lab location | 1 site (Oklahoma City, United States) |
| Project ID | NIH-11193814 on NIH RePORTER |
What this research studies
If you are a first-time mom with obesity scheduled for induction at term, you could be randomly assigned to receive prophylactic antibiotics during labor or a placebo. The team will track delivery outcomes such as whether you have a cesarean, postpartum infections, and other short-term maternal and newborn health measures. This is a multi-center, randomized, placebo-controlled effort that builds on a prior pilot suggesting benefit and aims to enroll many participants to confirm the effect. Participation involves receiving the antibiotic during labor, routine obstetric care, and brief follow-up after delivery.
Who could benefit from this research
Good fit: Ideal candidates are nulliparous (first-time) pregnant women with obesity scheduled for labor induction at term (around 39 weeks).
Not a fit: Women who are not first-time, not obese, have a planned cesarean or preterm delivery, or who are allergic to the study antibiotic are unlikely to benefit from this intervention.
Why it matters
Potential benefit: If successful, this could lower cesarean delivery rates and related infection and recovery complications for obese first-time mothers.
How similar studies have performed: A prior pilot randomized placebo-controlled trial from the investigators found a lower cesarean rate with prophylactic antibiotics in a similar population, but a larger multi-center trial is needed to confirm those results.
Where this research is happening
Oklahoma City, United States
- University of Oklahoma Hlth Sciences Ctr — Oklahoma City, United States (Active)
Researchers
- Principal investigator: Pierce, Stephanie — University of Oklahoma Hlth Sciences Ctr
- Study coordinator: Pierce, Stephanie
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.